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Enabling sustained communication with patients for safe and effective management of 




Aims: To examine how patients received, understood, and acted upon healthcare professional 
communication about their oral chemotherapeutic regimen throughout their treatment. 
 
Design: A longitudinal ethnographic study. 
 
Methods: Over 60 hours of observational data were recorded, in the form of field notes and 
audio-recordings from interactions between 9 oncology doctors, 6 oncology nurses, 8 patients 
and 11 family members over a period of six months in outpatient departments within one 
hospital in Northern Ireland.  Sixteen semi-structured interviews with patients and three focus 
groups with healthcare professionals were also carried out.  This study took place from October 
2013 to June 2016.  Data were thematically analysed. 
 
Results: Three themes where identified from the data.  These were initiating concordance 
through first communication about oral chemotherapy; which focused on initial 
communication during oncology consultations about oral chemotherapy, sustained 
communication of managing chemotherapy side effects; which was about how communication 
processes supported timely and effective side effect management, and un-sustained 
communication of oral chemotherapy medication-taking practice; when patients and healthcare 
professionals failed to communicate effectively about chemotherapy medication-taking. 
 
Conclusion: The two most important factors in ensuring the optimal management of oral 
chemotherapeutic medicines are early recognition and appropriate response to side effects and 
the maintenance of safe and effective medication administration.  This study found that 
oncology doctors and nurses engaged in sustained communication about the side effects of 
chemotherapy but did not focus their communication on safe administration after the first 
consultation. 
 
Impact: Based on this evidence, we recommend that healthcare professionals who provide oral 
chemotherapy for home administration should review their processes and procedures.  
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Healthcare professionals need to ensure that they embed frequent communication for the 
duration of treatment between themselves and patients, including open discussion and advice, 
about side effects and medication administration. 
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Cancer is a leading cause of death with almost 10 million deaths worldwide (World Health 
Organization, 2018).  Colorectal cancer is the third most common form of cancer and its global 
burden is expected to increase by 60% to more than 2.2-million new cases by 2030 (Arnold et 
al. 2017). 
 
There are several different treatment options recommended for people living with colorectal 
cancer including surgery, chemotherapy, targeted therapy, radiotherapy, or a combination of 
these approaches (Mitchell, 2013; National Institute of Clinical Excellence 2014).  
Chemotherapy treatment involves administering medications to impede cancer growth and kill 
cancer cells (National Comprehensive Cancer Network 2017).  5-fluorouracil is the most used 
type of chemotherapy for colorectal cancer, which is usually administered by a continuous 
pump as a 48-hour infusion, by weekly injections, or by daily injections (Marley and Nan 
2016).  However, in line with recent developments enabling oral administration of 
chemotherapeutic medications, the oral medication capecitabine has become widely 
administered internationally (Aguado et al. 2014). 
 
Oral administration of chemotherapy affords patients and healthcare professionals several 
advantages.  Patients can participate more actively in managing their chemotherapy. 
Convenience and flexibility in administering chemotherapeutic treatment are key advantages 
because patients can take their chemotherapy in tablet form at home (Oakley et al. 2010).  It is 
important that patients can safely administer their chemotherapy and can recognise and report 




Acceptance of the impact of communication on patient medication-taking practices is long 
established (Marcus-Varwijk et al, 2019; Royal Pharmaceutical Society 1999; Stevenson et al. 
2004; Tobiano et al. 2019; Young et al. 2019).  However, limited empirical studies have 
focused on people living with cancer who administer their own oral chemotherapeutic 
treatments in the community (Mitchell et al. 2014).  Current research about oral chemotherapy 
medication-taking practice has tended to focus on measuring adherence levels and subsequent 
implications for patients (Escalada & Griffiths 2006; Foulon et al. 2011; Given et al. 2011; 
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Partridge et al. 2002; Ruddy et al. 2009).  This focus on adherence is understandable given the 
narrow therapeutic index of the medication and the fact that patients administer treatment 
without professional supervision.  
 
Current research on chronic disease management demonstrates the importance of concordance 
in patient-healthcare professional communication (Hamann et al, 2014; Kehl et al. 2015; 
Mitchell et al. 2019; Siouta et al. 2016).  Concordance involves patients and healthcare 
professionals having agreed decisions about treatment based on equal relationships (Mead & 
Bower 2002; Mitchell 2014; Royal Pharmaceutical Society 1999).  Concordance is more likely 
to be achieved when communication focuses on what Jürgen Habermas (1984; 1987) terms the 
lifeworld of the patient.  The lifeworld relates to a person’s day-to-day experiences, 
perceptions, and interpretations of events, and comprises tacit and socially generated 
understandings that enable navigation of everyday life.    
 
Since administration of oral chemotherapy often takes place without professional supervision, 
it is reasonable to consider the role of concordance as more important than usual.  This is 
because any deviation from healthcare professional guidelines could lead to harmful toxicity 
or poor treatment efficacy and even prove fatal (Lea et al. 2018).  While consideration of the 
lifeworld is important, it is also imperative that the patient has knowledge and understanding 
about the importance of achieving therapeutic treatment levels safely (Barry et al. 2001; Gilbar 
and Carrington, 2005).  Errors with oral chemotherapy outside of the hospital are frequently 
reported in the literature (Given et al. 2011; Krikorian et al. 2018; Walsh et al. 2009). 
 
This study explores how communication about oral chemotherapy affects patient knowledge 
and behaviour over time.  This longitudinal approach was designed to illuminate the complex 





Aim and Objectives 
 
The aim of this study was to examine how patients received, understood, and acted upon 
healthcare professional communication about their oral chemotherapeutic regimen throughout 
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their treatment.  The objectives were to examine communication over a sustained period; and 
to establish patient understanding about oral chemotherapy, how communicating about self-
administration is maintained over time and how communication regarding side effects 
management is maintained over time.  
 
A full version of the research protocol can be found XXXX et al. (XXXX).  This study followed 




A longitudinal ethnographic approach was undertaken using observations, documentation 
analysis, semi-structured interviews, and focus groups (Hammersley & Atkinson 2007).   
 
Ethical Considerations and Recruitment 
 
This study was reviewed and approved by the Office of Research and Ethics Committee, 
Northern Ireland, June 2013 (Reference: 13/NI/0056), and by the Research Governance office 
of the relevant Health and Social Care Trust, June 2013 (Reference: 12144SP-SS).  Written 
consent was obtained from patients, families, oncologists, and nurses who participated in the 
study.  Recruitment occurred after patients’ diagnosis of colorectal cancer and prior to their 
initial consultations at the oncology clinic.  If the researcher conducting data collection 
identified a potentially harmful practice during patient interview, the researcher informed the 
patient about this issue following the interview.  Subsequently, the oncology team was also 
informed about any potential unsafe practices immediately by the patient via the 24-hour 
helpline.  During consultations, the observer was also obliged to inform oncology doctors or 
nurses if a patient did not disclose unsafe practice that the researcher was aware of through 





The study setting was in an oncology outpatient unit, in a large 900-bed university teaching 
hospital in Northern Ireland.  Patient participants were recruited from persons diagnosed with 
colorectal cancer and healthcare professional participants were those who worked with this 
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All participants were purposively recruited.  Patient participants had a first-time diagnosis of 
colorectal cancer, were prescribed capecitabine as part of their treatment and consented to 
observational data to be collected during their consultations with their oncologist and oncology 
nurses.  Patient participants also consented to participating in two semi-structured interviews 
about their experiences at mid-treatment and post-treatment.  Ten eligible patients received 
initial information about this study through their oncologists.  Nine patients went on to receive 
information about the study from the research team, and eight patients agreed to take part and 
provided written consent to be part of this research study.  All patient participants self-
administered their treatment at home for a period of six months.  Each patient participant 
attended a scheduled outpatient appointment with their oncology team every three weeks. 
 
Consent was also obtained from 11 family members who attended treatment appointments with 
each patient.  Healthcare professionals involved in patients’ care were also invited to 
participate.  All healthcare professionals involved in healthcare consultations received a 
comprehensive face-to-face presentation and detailed information sheet.   Written consent was 
obtained from 15 healthcare professionals prior to commencement of the study.  Healthcare 
professionals who participated in focus groups, which included doctors and nurses, also 
provided separate written consent.  Focus groups took place three months after all observations 
and interviews were completed.  Figure 1 provides an overview of the participant consent, 




The observer as participant stance enabled the researcher to observe participants during patient-
professional consultations and actively interact with patients to encourage reflections about the 
consultation process (Bernard, 2006; Frey, 2018).  The observer engaged with patients and 
family members during waiting periods before consultation.  However, during consultations, 
there was no observer involvement.  The type of data collected from observations involved 
audio recordings of consultations, field notes of patient and family visits to oncology clinics, 
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examination of information leaflets, and reflective journaling.  Observational data collection 
occurred at five different time-points in the patient journey, which comprised the first (day 1), 
second (day 21), third (day 42), sixth (day 126) and final appointment (day 168) for each of 
the patient participants.  These points of data collection were informed by an external expert 
steering group made up of oncologists, oncology nurses and people living with cancer.  The 
reason for this schedule was because the expert steering group felt important communication 
about patient safety and oral chemotherapy would be more likely to occur early in the patient 
journey.  Semi-structured interview with patient participants took place between the second 
and third appointment (approximately day 35-41) and a few weeks after the final appointment 
(approximately day 170-180).  The location of these interviews was determined by the patient 
and they mostly took place at their own residence.  Focus groups with healthcare professionals 
took place three months after full data collection of the final patient participant.  These focus 
groups were held on hospital premises.  Supplementary file two provides an overview of these 
data collection time points.  The research team also carried out an examination of publicly 
available information leaflets given to patients during their consultations.  Observations, 
interviews, and focus groups were recorded on a digital audio recorder.  In addition, field notes 
and a reflective diary were recorded and maintained throughout this study and these were 




Data were analysed using inductive thematic analysis involving a six-step approach (Braun and 
Clarke, 2006).  The first step was familiarisation of data through audio transcription by the first 
author.  The next steps were coding of the data and subsequent generation of broad themes by 
the research team.  Steps four and five involved the research team reviewing and defining their 
themes over several months.  The final step in the process was writing up the findings (Braun 
and Clarke, 2006).  The data were analysed by the research team using Habermas’ Theory of 
Communicative Action (Habermas 1984;1987).  In the context of this study, Habermasian 
theory was used to illuminate how patient-professional communication could achieve mutual 
understanding and recommended action. 
 




To improve the trustworthiness of research data, the four criteria of credibility, transferability, 
dependability, and confirmability were followed (Lincoln & Guba, 1985).  Participants were 
provided with their interview or observation transcripts as a check of the data that were 
collected.  Field notes were maintained about the research setting and comprehensive record-
keeping was undertaken throughout the research process.  Regular team meetings ensured an 
appropriate audit trail was followed and reflexivity was addressed using a reflective diary that 
was updated after each episode of data collection.  The reflexive diary was used as an ongoing 
check of the observer’s experiences, perceptions and reflections, as a log of the data collection 
activities as they occurred and as a record of the methodological decisions made during the 
research process (Smith, 1999).  In addition, independent thematic analysis by all team 





Data collection consisted of 40 separate observations totalling approximately 60 hours, 
examination of 19 information leaflets given to patients, 16 semi-structured interviews with 
patients in receipt of oral chemotherapy and three focus groups with oncologists and oncology 
nurses.  Study participants included eight people receiving oral chemotherapy, eleven family 
members, nine oncologists and six nurses.  This study took place from October 2013 to June 
2016.  Patient characteristics are described in Table 1. 
 
Three themes were identified.  The first theme was initiating concordance through first 
communication about oral chemotherapy.  The second theme was sustained communication of 
managing chemotherapy side effects, and the third theme comprised un-sustained 
communication of oral chemotherapy medication-taking practice. 
 
Initiating Concordance through First Communication about Oral Chemotherapy 
 
All 8 patient participants and their families followed a similar journey throughout the course 
of their treatment (supplementary file three).  The primary topic of conversation during first 
contact with patients always related to maintaining safety throughout oral chemotherapeutic 
treatment.  The information communicated by oncology doctors and nurses included: the 
importance of medication adherence, use of the 24-hour helpline to report side effects; and 
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ways in which to manage diarrhoea, erythema, hair loss and rarer side effects.  During this 
initial contact, healthcare professionals did not appear to refer to patients’ particular lifeworld 
because communication was not personalised and all patients received the same information 
irrespective of the stage of their disease, gender, age or whether they had a family member 
present.  Typical excerpts are highlighted as follows:  
 
Doctor 1: Some patients on chemo become nauseous and we are going to prescribe you some 
anti-sickness medications as a precaution.  (Observation 1: Patient 1)   
 
Nurse 4: If you even feel tenderness on the soles of your feet, do be sure and tell us the next 
time.  Use loads of moisturising cream [on feet] and if you are sitting in the house at night just 
kick off the shoes and let the fresh air go around your feet.  (Observation 1: Patient 6) 
 
Information given by healthcare professionals was supplemented by standardised information 
leaflets to patients about the side effects of chemotherapy.  The usefulness of these resources 
was positively appraised by patients and their families as these provided a source of 
information that patients and family members could return, to if needed.  However, the patient 
information leaflets were not specific to oral chemotherapy and therefore did not address the 
unique challenges associated with self-administration, adherence, and storage of medication.    
 
While both physicians and nurses engaged in communication about management of side 
effects, practical details about how oral chemotherapy should be administered, handled, stored, 
and diluted were exclusively the role of oncology nurses.  Throughout their practical 
demonstrations (for example demonstrating non-touch technique), oncology nurses routinely 
engaged with the lifeworld of patients.  Patients engaged in shared decision-making about how 
they could correctly take their medication, which included safely diluting medication to 
overcome swallowing difficulties: 
 
Beverley: Oh God, I will never be able to swallow those big things [oral chemotherapy]. 
Nurse 4: I can show you how to dissolve them if you like?  It is straight-forward. 
Beverley: No love, I will manage sure – will get used to them. 
Nurse 4: Tell you what…I will show you how to dissolve these tablets and if you are finding 





Practical advice about oral chemotherapy medication-taking practice was not supplemented by 
any information leaflets.  The absence of this supplementary information coupled with the fact 
that oncology doctors did not routinely discuss medication-taking appeared to deprioritise the 
issue from patients and family members.  During the first semi-structured interviews, which 
occurred between appointments two and three, patients frequently recalled the importance of 
side effect recognition and management, but few reflected on information they received about 
medication-taking practice. 
 
Hugo: The first consultation went well, but there was a lot to take in.  The main message I got 
was that I needed to be vigilant when taking the tablets.  Any temperature, or loose bowel 
motion or sickness…whatever…I needed to keep an eye on it and contact the cancer doctors 
immediately.  (Semi-Structured Interview 1, Patient 8) 
 
Estelle: The doctor was very serious, and I was trying to keep it light-hearted because I was 
nervous, you know?  He [oncology doctor] was telling me about all the different ways that 
these things [oral chemotherapy] could kill me [laughs]! (Semi-Structured Interview 1, Patient 
5) 
 
Initiating concordance was a key goal of healthcare professionals during first contact with 
patients.  Communication focused on reinforcing the importance of recognising side effects, 
and managing a medical-led consultation, a nurse-led consultation and the provision of 
supportive literature on chemotherapy.  While medication-taking practice was an important 
part of nurse consultations, the lack of physician involvement and specific literature on oral 
chemotherapy meant that medication-taking did not appear to have the same significance as 
recognising and managing side effects.  
 
Sustained Communication of Managing Chemotherapy Side Effects 
 
After the first outpatient appointment, healthcare professionals consistently revisited the issue 
of patient recognition and management of side effects over the next six months.  Reaffirming 
the patient and family knowledge base about the importance of side effects was the primary 




Management of chemotherapy side effects was a shared responsibility between the healthcare 
professional team, the patient, and their families.  Open dialogue between patients and 
healthcare professionals facilitated shared understandings about the impact of living with 
chemotherapy and spoke directly to the lifeworld of these patients.  The disclosure of these 
side effects and the impact they caused the patient, enabled the oncology team to prescribe 
appropriate pharmacological and non-pharmacological approaches to support patients during 
their treatment, as highlighted in the excerpt from the reflective diary. 
 
Diary: “what about your stomach, any diarrhoea?” Once Gerry disclosed this information, 
the doctor quickly drew up a treatment plan by prescribing ondansetron and offering dietary 
advice…Gerry’s diarrhoea improved greatly for the remainder of his treatment and he 
eventually stopped his medication and managed his symptoms by his diet.  (Reflection 3, 
Patient 7 & Reflection 6, Patient 7). 
 
Early disclosure of side effects was associated with better management strategies.  Patients 
who shared experiences about the impact of chemotherapy on their lifeworld were more likely 
to maintain concordance and reach a shared decision with healthcare professionals about what 
approach could work best for them.  In the following excerpt, Dot the patient and her daughter 
Debbie discussed how challenges with sleeping were overcome. 
 
Dot: I am getting there now but it was a long few weeks.  I have sleeping tablets in case I need 
them, but I do not need these all the time.  I do the relaxation exercises before bed. 
Debbie: Yes, the [oncology] nurse was excellent, and she put us in touch with the counselling 
services which was very helpful.  She recommended that my mum reads or takes a bath before 
bed to unwind and surprisingly those little things worked for her.  (Semi-Structured Interview 
1: Patient 4) 
 
Facilitating shared discussions about side effect recognition and management relied on 
balancing the voice of the medical expert and the voice of the lifeworld.  In the absence of 
patient-led disclosures about the side effects of treatment, healthcare professionals frequently 
used consultations to reaffirm the importance of recognising and managing the side effects of 
oral chemotherapy.  Healthcare professionals defended this approach and conceded that 
because patients had to receive a large amount of information that was critical to their safety, 
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communication could often be repetitious and non-personalised.  This issue was identified in 
focus groups with healthcare professionals. 
 
Doctor 4: When you think about it, it is [giving information about oral chemotherapy] a bit 
like a script.  We as doctors, it is the same for the nurses too, have a great deal of things to get 
across to the patient, you know?  I do not think there is really another way to do it.  (Focus 
Group 2) 
 
An important element of sustaining communication about recognition and management of side 
effects, was the presence of a 24-hour helpline.  Access to this helpline enabled patients to 
overcome any concerns about chemotherapy side effects through immediate communication 
with a healthcare professional.  This mechanism acknowledged that patients had expertise in 
their body’s experience of illness and that they could seek immediate medical expertise in the 
event of unmanageable chemotherapy side effects.  Despite regular communication about this 
service, most patients were initially reluctant to engage with the helpline service when first 
confronted with a problematic side effect.  Six patients and families did not use the 24-hour 
helpline and instead they contacted their own primary care physicians about the side effects of 
chemotherapy.  Patients identified various reasons for contacting the primary care physician 
first.  Most stated that they either thought side effects were not severe enough to contact the 
oncology team, or that they knew how busy the outpatient unit was and did not want to waste 
the time of the oncology team.  However, even though most patients did not utilise the 24-hour 
helpline effectively in the first instance, professional feedback about the dangers of not 
informing the oncology service about side effects, combined with patients’ own experiences of 
the negative consequences of not doing so, powerfully reinforced concordance on this issue 
during the course of treatment.  By the conclusion of the study, all eight patient participants 
had contacted the help-line number at least once as illustrated in the excerpt that follows. 
 
Carol: I was very sick to tell you the truth.  I had a really high temperature, chest palpations 
and could not keep anything down [vomiting].  I called my GP [General Practitioner] and 
eventually went to A&E [Accident and Emergency Department]…It never really occurred to 
me that I should phone the helpline, but after that experience, I certainly did use that number 




Sustained communication about side effects was beneficial to patients throughout their 
treatment journey.  The process facilitated safe treatment and empowered patients to engage in 
shared decision-making about managing side effects.  It also recognised the need to persistently 
engage with patients’ understandings and interpretations to ensure that their lifeworld concerns 
about being a burden did not prevent them from seeking appropriate help. 
 
Un-Sustained Communication of Oral Chemotherapy Medication-Taking Practice 
 
In contrast to the efforts made to sustain communication about the recognition and management 
of side effects, patients’ oral chemotherapy medication-taking practice was seldom considered 
in professional-patient communication after the initial consultation.  During the six-month 
course of chemotherapy, only two patients were explicitly asked about their adherence to their 
oral chemotherapy regimen by oncology nurses.  Three patients did not correctly adhere to 
their regimen.  Estelle missed several doses, Beverley missed six doses and Dot missed two 
doses over the course of their treatment.  All these patients chose to take their missed dose 
along with their next scheduled dose of chemotherapy and none intended to inform their 
oncology team.  An example of this situation is highlighted in the excerpt below. 
 
Estelle: It won’t do me any harm [missing a dose]…I just took double the next day…You have 
two weeks’ worth of tablets, so any time I missed some, I just took some the next day when I 
remembered.  (Semi-Structured Interview 1: Patient 5). 
 
These occurrences demonstrated that, in the absence of sustained communication from the 
expert world of the healthcare professional about adherence, there were divergences of 
understanding about safe administration that could develop over time.  These divergences of 
understanding were solved by patients in their own manner, which inevitably involved recourse 
to their lifeworld interpretations.  Moreover, in the absence of consistent feedback between 
patients and healthcare professionals about adherence, there was no mechanism for healthcare 
professionals to identify and address potentially dangerous modes of self-administration.    
 
Irregularities in dosage were not the only risky consequences of lack of sustained 
communication.  Another problem related to medication-taking practice.  Once again, 
healthcare professionals’ communication with patients and families about how oral 
chemotherapy should be administered was not sustained beyond the initial appointment.  In the 
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observations that occurred over the next six months, no oncology doctor or nurse checked to 
see how patients administered their oral chemotherapy.  Four patients, Beverley, Carol, Estelle, 
and Hugo did not use safe handling practices as advised in their initial consultation, for example 
touching their chemotherapy with their hands, as noted in the excerpt that follows. 
 
Carol: I think I asked her [Nurse 3] about touching them [the oral chemotherapy tablets] and 
she said to make sure my hands were clean beforehand and that you can touch your tablets 
and put them in your mouth, I think that is right…Then just hygiene all the time.  Is that right? 
(Semi-Structured Interview 2: Patient 3). 
 
Another example of poor medication-taking practice relates to Fiona who did not follow the 
initial instructions that she received from the oncology nurse about dissolving oral 
chemotherapy tablets to make swallowing the medication easier.  According to the 
manufacturer guidelines, capecitabine tablets should never be crushed as the medication 
residue released from crushing is toxic. 
 
Fiona: They [healthcare professionals] told me to dissolve them [oral chemotherapy], but I 
actually had to crush them [with a pestle and mortar] because it took them that long to dissolve 
in water and see every time I went in and looked at them – I was getting sicker and sicker 
because of the anxiety [of waiting to take that chemotherapy] so it made it worse.  (Semi-
Structured Interview 2: Patient 6). 
 
The absence of direct input from the medical expert about medication-taking practice meant 
that patients used approaches based on their lifeworld understandings and interpretations, to 
overcome challenges that resulted from medication administration within the context of their 
everyday lives.  During this study, several patients disclosed medication-taking practice that 
was not recommended by their oncology team, relating to the re-use of medication pots, storage 
of oral chemotherapy and use of water for swallowing tablets.  While no participants in this 
study suffered harm, the paucity of professional-patient communication about medication-
taking throughout the patient journey could be extremely dangerous for people self-







Initial professional communication focused on ensuring patients had the knowledge to safely 
self-administer their medication and recognise side effects of chemotherapy.  As the patient 
journey continued, professional communication about management of side effects was 
sustained over time and this topic was consistently revisited.  This consistent practical 
rechecking of understanding was very important as it supported patients receiving oral 
chemotherapy and their families, to identify harmful side effects, to take appropriate action 
throughout treatment and to facilitate overall concordance with the treatment regimen.  
Sustaining this communication also enabled healthcare professionals to engage with and 
influence the lifeworld perspectives of patients by, for example, repeated reassurance that using 
the helpline when experiencing toxicity was not a burden on cancer services.  Such practice 
has been regularly reported and advocated in the international literature (Flannery et al. 2013; 
Oncology Nursing Society, 2016; Reid and Porter, 2011).  In contrast, communication about 
medication-taking practice was not sustained beyond the initial appointment.  This situation 
sometimes led to patient participants’ unmediated reliance on their lifeworld understandings 
and interpretations in solving problems they faced in relation to the administration of their 
medication.  This, in turn, led to patients engaging in some physically hazardous practices. 
 
Concentration on side effects management is important because of the harmful toxicities 
associated with oral chemotherapy (Foulon et al. 2011; Jacobs et al. 2018).  Healthcare 
professionals needed to equip patients with information about how to effectively recognise and 
report side effects in a timely manner.  This information was arguably much more complex to 
communicate when considered alongside talking to patients about how to self-administer oral 
medication.    It is possible that healthcare professionals assumed that patients could administer 
their own medication.  However, literature reviews have identified poor adherence to oral 
chemotherapy as an important and recurring issue (Foulon et al. 2011; Given et al. 2011; Jacobs 
et al. 2018).  Self-administration of oral chemotherapy is an activity performed away from the 
regulated and controlled context of the clinical arena.  Instead, it occurs amid people’s everyday 
lives, with all the challenges that these involve; challenges that can often impact on their 
treatment regimen.  If they are left to their own devices, people will use the interpretative tools 
that they have developed within their own lifeworlds to respond to those challenges (Manias et 
al. 2007).  The problem is that it is unlikely that these tools will fully equip patients to respond 
safely to the unique issue of administering highly toxic substances.  Errors in administration 
have already been reported in previous research about oral chemotherapy (Escalada & Griffiths 
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2006; Foulon et al. 2011; Given et al. 2011; Jacobs et al. 2018; Mitchell et al. 2014; Partridge 
et al. 2002; Ruddy et al. 2009).      
 
There is evidence from the work of Barry et al. (2001) that when patients share their lifeworld 
during consultations, it is beneficial.  This facilitates the presentation of the patient’s own 
personal agenda, for example their voicing of unique psychological or physical issues.  The 
challenge for cancer care professionals is to help patients incorporate expertise in the 
administration of potentially dangerous chemotherapy into their lifeworld.  In attitudinal terms, 
this requires an appreciation of the everyday challenges that patients face and a respect for their 
understandings of, and strategies to deal with those challenges.  Such practice has been 
acknowledged as a cornerstone of concordance in the context of management of other long-
term conditions (De Las Cuevas 2011; Manias et al. 2007; Manias 2010; Snowden et al. 2014).  
In behavioural terms, it requires sustained communication and support to ensure that patients’ 
responses to the problems that arise of incorporating the administration of oral chemotherapy 





This study focused on patients who were diagnosed with colorectal cancer and prescribed one 
oral chemotherapeutic medication, capecitabine.  Transferability of these findings to other 
cancer types or oral chemotherapeutic regimens may be limited because patients may be on 
multiple medications for treating their cancer condition.  Similarly, the research reported on 
communication practices in one cancer centre.  As such, its descriptive findings may not be 
transferrable to the practices of other units that dispense oral chemotherapy.  A further 
limitation is the possible Hawthorne effect associated with the ethnographic methodology, 
whereby healthcare professionals and patients may modify their normal behaviours and 
practice due to being observed.  The research team followed best practice to reduce the impact 




The two most important factors in ensuring the optimal management of oral chemotherapeutic 
medicines are early recognition and appropriate response to side effects, and the maintenance 
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of safe and effective medication administration.  This study found that oncology doctors and 
nurses engaged in sustained communication about the side effects of chemotherapy but did not 
sustain their communication about safe administration after the first consultation.    
 
Patients’ responses to these differing approaches indicated that continuing communication over 
the full course of treatment had the effect of encouraging safe practice while the absence of 
continued communication increased the risk of dangerous practice by self-administering 
patients.  The aim of that communication should be to establish concordance, which in turn 
requires healthcare professionals to appreciate the everyday challenges faced by patients and 
to engage respectfully but informatively in their responses to those challenges.  
 
Based on this evidence, we recommend that healthcare professionals who provide oral 
chemotherapy to patients for home administration, should review their processes and 
procedures.  Healthcare professionals need to ensure that they embed frequent communication 
for the duration of treatment between themselves and patients, including open discussion and 
advice, about side effects and medication administration. 
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